BioLargo, Inc. Engagement Extension Agreement
Ex. 10.1
Engagement Extension Agreement
September 30, 2015
This Engagement Extension Agreement (the “Extension”) references the Engagement Agreement and Scope Letter dated February 1, 2008 (“2008 Agreement”) by and between CFO 911 Corporation (the “Advisor)” and BioLargo, Inc. (the “Company”), and written extensions to the Agreement (the “Prior Extensions”), pursuant to which Xxxxxxx X. Xxxxxx XX has been serving as the Company’s Chief Financial Officer. The parties desire to extend the terms of the prior agreements for a period of one year, pursuant to the terms of this Extension. The 2008 Agreement, the Prior Extensions and this Extension are collectively referred to herein as the “Agreement”.
Except as expressly amended or modified herein, all terms and conditions set forth in the 2008 Agreement and Prior Extensions are incorporated herein by this reference, and continue to be in full force and effect. The parties acknowledge and confirm that Xx. Xxxxxx has been serving as the Company’s Chief Financial Officer, and continues to do so through today’s date. Retroactively effective as of February 1, 2015, the Advisor and the Company hereby agree to extend the Term of the engagement as set forth in the 2008 Agreement to expire September 30, 2016 (the “Extended Term”). Notwithstanding the foregoing, either party may terminate this Agreement upon 30 days’ written notice. Upon the expiration of this Agreement on September 30, 2016, unless this agreement has been terminated, Advisor shall continue to serve as the Company’s Chief Financial Officer until new terms are agreed upon.
All terms regarding compensation to the Advisor are amended and replaced by the following. During the Extended Term, the Advisor shall receive the compensation as set forth in this Extension. The Company shall issue to Xxxxxxx X. Xxxxxx XX an option (the “Option”) to purchase 300,000 shares of the Company’s common stock, pursuant to the Company’s 2007 Equity Incentive Plan. The Option shall vest over a period of 12 months, with 120,000 shares having vested as of September 30, 2015, and the remaining shares to vest monthly beginning October 1, 2015, and each month thereafter, 15,000 each month, so long as this Agreement is in full force and effect. The Option shall be exercisable at $0.57 per share, and shall expire September 30, 2025.
AGREED TO AND ACCEPTED THIS 29th DAY OF SEPTEMBER, 2015
|
CFO 911 CORPORATION |
|
BioLargo, Inc. |
| ||
|
0000 X. Xxxxxxxxxx Xxx., Xxxxx 000 |
|
0000 X. Xxxxx Xxx. |
| ||
|
Xxxxx xxx Xxx, XX 00000 |
|
Xxxxx Xxx, XX 00000 |
| ||
|
|
|
|
|
|
|
|
By: |
/S/XXXXXXX X. XXXXXX XX |
|
By: |
/S/XXXXXX X. XXXXXXX |
|
|
Name: |
Xx. Xxxxxxx X. Xxxxxx XX |
|
Name: |
Xx. Xxxxxx X. Xxxxxxx |
|
|
Title: |
Chief Executive Officer |
|
Title: |
President |
|
|
Date Signed: Sept 30, 2015 |
|
Date Signed: Sept 30, 2015 |
| ||
